• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

Upbeat performance in Q4

Quote

anonymous

Guest
Medtronic posted better-than-expected fourth quarter earnings. Earnings came in at $1.07 a share. Excluding items, the company earned $1.42, topping analysts’ estimate of $1.39. Revenue came in at $8.1 billion, meeting the consensus estimate of $8 billion. Strong global demand for the new sensor-augmented insulin pump systems, boosted the total sales of diabetes unit by 26% to $645 million.
Source: https://news.alphastreet.com/medtronic-q4-earnings/
 






Met revenue target and exceed earnings target. That is great for stockholders; not so much for employees.

We are being squeezed like dried out fruit in a Vitamix in order to achieve these efficiencies. Not sustainable.
 








anonymous said:
Met revenue target and exceed earnings target. That is great for stockholders; not so much for employees.

We are being squeezed like dried out fruit in a Vitamix in order to achieve these efficiencies. Not sustainable.
Click to expand...

I've been here 15 years and 98% of the changes required more work for less total compensation/benefits. I'll leave soon unless MN starts valuing productive employees again. Fortunately, it's a great job market despite what Omar seems to think!
 








Top Bottom
Back
Quote